PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.38%
Revenue growth at 50-75% of AVGO's 2.54%. Martin Whitman would worry about competitiveness or product relevance.
2.44%
Gross profit growth at 50-75% of AVGO's 3.45%. Martin Whitman would question if cost structure or brand is lagging.
1.49%
EBIT growth below 50% of AVGO's 7.65%. Michael Burry would suspect deeper competitive or cost structure issues.
4.16%
Operating income growth at 50-75% of AVGO's 7.65%. Martin Whitman would doubt the firm’s ability to compete efficiently.
0.83%
Net income growth under 50% of AVGO's 25.65%. Michael Burry would suspect the firm is falling well behind a key competitor.
0.96%
EPS growth under 50% of AVGO's 25.71%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
0.98%
Diluted EPS growth under 50% of AVGO's 27.27%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
-0.11%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
14.47%
Positive OCF growth while AVGO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
11.93%
Positive FCF growth while AVGO is negative. John Neff would see a strong competitive edge in net cash generation.
66.03%
10Y revenue/share CAGR under 50% of AVGO's 571.10%. Michael Burry would suspect a lasting competitive disadvantage.
37.03%
5Y revenue/share CAGR at 50-75% of AVGO's 71.79%. Martin Whitman would worry about a lagging mid-term growth trajectory.
14.40%
3Y revenue/share CAGR under 50% of AVGO's 39.71%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
164.44%
10Y OCF/share CAGR under 50% of AVGO's 892.55%. Michael Burry would worry about a persistent underperformance in cash creation.
86.38%
Below 50% of AVGO's 253.40%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
21.04%
3Y OCF/share CAGR under 50% of AVGO's 64.46%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
301.53%
Below 50% of AVGO's 677.82%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
118.16%
Below 50% of AVGO's 705.04%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
30.19%
Below 50% of AVGO's 63.70%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
36.59%
Below 50% of AVGO's 677.98%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
28.13%
5Y equity/share CAGR 1.25-1.5x AVGO's 20.26%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
21.31%
Positive short-term equity growth while AVGO is negative. John Neff sees a strong advantage in near-term net worth buildup.
688.88%
Below 50% of AVGO's 4122.73%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
167.47%
Below 50% of AVGO's 608.75%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
64.28%
3Y dividend/share CAGR at 50-75% of AVGO's 115.37%. Martin Whitman might see a weaker short-term approach to distributing cash.
3.90%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
0.38%
Inventory shrinking or stable vs. AVGO's 15.54%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
12.96%
Asset growth above 1.5x AVGO's 0.47%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
8.95%
BV/share growth above 1.5x AVGO's 1.18%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
23.80%
Debt growth far above AVGO's 0.05%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-0.77%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-3.06%
We cut SG&A while AVGO invests at 6.46%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.